Tetrylammonium

Tetrylammonium

SCHEMBL1974121

CC[N+](CC)(CC)CC.CC[N+](CC)(CC)CC.CC[N+](CC)(CC)CC.CC[N+](CC)(CC)CC.CC[N+](CC)(CC)CC.CC[N+](CC)(CC)CC.CC[N+](CC)(CC)CC.CC[N+](CC)(CC)CC.[O-]B([O-])F.[O-]B([O-])F.[O-]B([O-])F.[O-]B([O-])F

nearest known ligand 0.57

Full drug profile on Sugi Atlas →

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.57
NFKB1 P19838 1/20 0.57
KCNA1 Q09470 1/20 0.57
KDM4E B2RXH2 1/20 0.53
PMP22 Q01453 1/20 0.53
ATM Q13315 1/20 0.53
DNM1 Q05193 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Tetrylammonium SCHEMBL1248212 1.00 TSHR (0.57) TSHRNFKB1KCNA1KDM4EPMP22
Tetrylammonium SCHEMBL624470 1.00 TSHR (0.57) TSHRNFKB1KCNA1KDM4EPMP22
Tetrylammonium SCHEMBL28740960 0.93 TSHR (0.57) TSHRNFKB1KCNA1KDM4EPMP22
Tetrylammonium SCHEMBL10770115 0.86 TSHR (0.42) TSHRNFKB1KCNA1KDM4EPMP22
Tetrylammonium SCHEMBL814834 0.85 TSHR (0.67) TSHRNFKB1KCNA1KDM4EPMP22
Tetrylammonium SCHEMBL4340516 0.85 TSHR (0.67) TSHRNFKB1KCNA1KDM4EPMP22
Tetrylammonium SCHEMBL4057767 0.85 TSHR (0.67) TSHRNFKB1KCNA1KDM4EPMP22
Tetrylammonium SCHEMBL8119298 0.85 TSHR (0.67) TSHRNFKB1KCNA1KDM4EPMP22
Tetrylammonium SCHEMBL2427604 0.81 TSHR (0.61) TSHRNFKB1KCNA1KDM4EPMP22
Tetrylammonium SCHEMBL28564114 0.81 TSHR (0.61) TSHRNFKB1KCNA1KDM4EPMP22

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2912008-B1 PROCESS FOR PREPARING 2-METHOXYMETHYL-1,4-BENZENEDIAMINE AND SALTS THEREOF NOXELL CORP (US) 2020-08-05 EP claimed
EP-3131152-A1 FLAME RETARDANT BATTERY ELECTROLYTES CONTAINING PHOSPHORIC ACID ESTERS LANXESS Deutschland GmbH (DE) 2017-02-15 EP claimed
EP-1505057-B1 METHOD OF PURIFYING QUATERNARY ALKYLAMMONIUM SALT STELLA CHEMIFA KABUSHIKI KAISHA (JP) 2011-06-22 EP claimed
EP-1289031-A2 Method of manufactoring a structured conducting polymer layer Technische Universität Braunschweig (DE) 2003-03-05 EP claimed
US-12567751-B2 Formation process for a potassium-ion hybrid super-capacitor COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) 2026-03-03 US disclosed
US-11608350-B2 Compositions and methods comprising conductive metal organic frameworks and uses thereof MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2023-03-21 US disclosed
US-20230077860-A1 FORMATION PROCESS FOR A POTASSIUM-ION HYBRID SUPER-CAPACITOR COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) 2023-03-16 US disclosed
US-20210009617-A1 COMPOSITIONS AND METHODS COMPRISING CONDUCTIVE METAL ORGANIC FRAMEWORKS AND USES THEREOF MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2021-01-14 US disclosed
US-10822364-B2 Compositions and methods comprising conductive metal organic frameworks and uses thereof MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2020-11-03 US disclosed
EP-3293745-B1 ADDITIVE MATERIAL FOR AN ELECTRODE OF AN ELECTROCHEMICAL CELL, DOUBLE LAYER CAPACITOR AND A METHOD FOR MANUFACTURING AN ELECTRODE OF THE SAME HERAEUS BATTERY TECH GMBH (DE) 2019-08-14 EP disclosed
US-20190211043-A1 COMPOSITIONS AND METHODS COMPRISING CONDUCTIVE METAL ORGANIC FRAMEWORKS AND USES THEREOF MASSACHUSETTS INSTITUTE OF TECHNOLOGY 2019-07-11 US disclosed
EP-3337801-B1 METHOD FOR THE PREPARATION OF (4S)-4-(4-CYANO-2-METHOXYPHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1-6-NAPHTHYRIDINE-3-CARBOXAMIDE AND RECOVERY OF (4S)-4-(4-CYANO-2-METHOXYPHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1-6-NAPHTHYRIDINE-3-CARBOXAMIDE BY ELECTROCHEMICAL METHODS Bayer Pharma AG (DE) 2019-06-12 EP disclosed
US-6469888-B1 Non-aqueous electrolyte electric double-layer capacitor BRIDGESTONE CORPORATION (JP) 2002-10-22 US disclosed
EP-1133514-A1 METHOD FOR THE ELECTROCHEMICAL DETECTION OF NUCLEIC ACID OLIGOMER HYBRIDS Friz Biochem GmbH (DE) 2001-09-19 EP disclosed
EP-1101230-A1 CHARGE STORAGE DEVICES Energy Storage Systems Pty, Ltd (AU) 2001-05-23 EP disclosed
WO-2000031101-A1 METHOD FOR THE ELECTROCHEMICAL DETECTION OF NUCLEIC ACID OLIGOMER HYBRIDS FRIZ BIOCHEM GMBH (DE) 2000-06-02 WO disclosed
US-6064560-A Active carbon and process for its production MITSUBISHI CHEMICALS CORPORATION (JP) 2000-05-16 US disclosed
WO-1999053510-A1 CHARGE STORAGE DEVICES ENERGY STORAGE SYSTEMS PTY. LTD. (AU) 1999-10-21 WO disclosed
EP-0009697-B1 PROCESS FOR PREPARING N-(ALPHA-METHOXY-ALKYL) URETHANES AND N-(ALPHA-METHOXY-ALKYL) URETHANES BAYER AG (DE) 1981-09-23 EP disclosed
EP-0009697-A2 Process for preparing N-(alpha-methoxy-alkyl) urethanes and N-(alpha-methoxy-alkyl) urethanes BAYER AG (DE) 1980-04-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190211043-A1 COMPOSITIONS AND METHODS COMPRISING CONDUCTIVE METAL ORGANIC FRAMEWORKS AND USES THEREOF ILK, AOC1, OCIAD2 TSHR 4769/4885NFKB1 4078/4885KCNA1 133/4885
US-10822364-B2 Compositions and methods comprising conductive metal organic frameworks and uses thereof ILK, AOC1, OCIAD2 TSHR 4769/4885NFKB1 4078/4885KCNA1 133/4885
US-12567751-B2 Formation process for a potassium-ion hybrid super-capacitor KCNK10, KCNJ8, KCNH2 TSHR 4040/4885NFKB1 1653/4885KCNA1 46/4885
US-11608350-B2 Compositions and methods comprising conductive metal organic frameworks and uses thereof ILK, AOC1, OCIAD2 TSHR 4769/4885NFKB1 4078/4885KCNA1 133/4885
US-20210009617-A1 COMPOSITIONS AND METHODS COMPRISING CONDUCTIVE METAL ORGANIC FRAMEWORKS AND USES THEREOF ILK, AOC1, OCIAD2 TSHR 4769/4885NFKB1 4078/4885KCNA1 133/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.